Thu, August 11, 2022
Wed, August 10, 2022
Tue, August 9, 2022
Mon, August 8, 2022

Marc Goodman Maintained (ACAD) at Buy with Decreased Target to $21 on, Aug 9th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-21-on-aug-9th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Marc Goodman of SVB Leerink, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Decreased Target from $27 to $21 on, Aug 9th, 2022.

Marc has made no other calls on ACAD in the last 4 months.



There are 4 other peers that have a rating on ACAD. Out of the 4 peers that are also analyzing ACAD, 2 agree with Marc's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Neena Bitritto-Garg of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $15 on, Monday, August 8th, 2022
  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $19 on, Tuesday, June 21st, 2022


These are the ratings of the 2 analyists that currently disagree with Marc


  • Ritu Baral of "Cowen & Co." Maintained at Buy with Decreased Target to $21 on, Monday, August 8th, 2022
  • Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $26 on, Tuesday, June 21st, 2022

Publication Contributing Sources